Clinical practice versus guidelines for the screening of cystic fibrosis-related diabetes: A French survey from the 47 centers.
Fiche publication
Date publication
juin 2022
Journal
Journal of clinical & translational endocrinology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ABELY Michel
Tous les auteurs :
Weiss L, Ronsin O, Reynaud Q, Abely M, Mely L, Burgel PR, Beltrand J, Kessler L
Lien Pubmed
Résumé
This study aimed to analyze clinical practices concerning cystic fibrosis-related diabetes (CFRD) screening in France. A web-based questionnaire was distributed between December 1, 2020 and January 31, 2021 among 47 cystic fibrosis centers including pediatric, adult, and mixed units. In accordance with guidelines, 92.8% of CF centers performed annual oral glucose tolerance tests (OGTT). Overall, 86.3% of CF centers performed 1- and 2-hour blood glucose determinations following OGTT. The OGTT was conducted before 10 years of age in 73% of pediatric centers. Continuous glucose monitoring (CGM) and laboratory glycated hemoglobin were employed for CFRD screening in 86.5% and 50% of centers, respectively. CGM was carried out in 69% of centers after glucose tolerance abnormalities had been detected in OGTT. Most CF centers used OGTT and CGM for CFRD screening. Studies are required to assess CGM usefulness as a validated tool in CFRD screening.
Mots clés
Continuous glucose monitoring, Cystic fibrosis, Diabetes, OGTT, Screening
Référence
J Clin Transl Endocrinol. 2022 Jun;28:100298